GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ocumetics Technology Corp (TSXV:OTC) » Definitions » Sloan Ratio %

Ocumetics Technology (TSXV:OTC) Sloan Ratio % : 0.00% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ocumetics Technology Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Ocumetics Technology's Sloan Ratio for the quarter that ended in Mar. 2024 was 0.00%.

Warning Sign:

When sloan ratio (-140.54)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.

As of Mar. 2024, Ocumetics Technology has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Ocumetics Technology Sloan Ratio % Historical Data

The historical data trend for Ocumetics Technology's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocumetics Technology Sloan Ratio % Chart

Ocumetics Technology Annual Data
Trend Jul20 Jul21 Dec22 Dec23
Sloan Ratio %
- -41.58 -38.86 -140.54

Ocumetics Technology Quarterly Data
Jul20 Jul21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.06 -131.37 -85.81 - -

Competitive Comparison of Ocumetics Technology's Sloan Ratio %

For the Medical Instruments & Supplies subindustry, Ocumetics Technology's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocumetics Technology's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Ocumetics Technology's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Ocumetics Technology's Sloan Ratio % falls into.



Ocumetics Technology Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Ocumetics Technology's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(-3.644--2.046
--0.142)/1.036
=-140.54%

Ocumetics Technology's Sloan Ratio for the quarter that ended in Mar. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Mar. 2024 )
=(-3.599--1.854
--0.151)/0.947
=-168.32%

Ocumetics Technology's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was -1.499 (Jun. 2023 ) + -0.749 (Sep. 2023 ) + -0.72 (Dec. 2023 ) + -0.631 (Mar. 2024 ) = C$-3.60 Mil.
Ocumetics Technology's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was -0.482 (Jun. 2023 ) + -0.723 (Sep. 2023 ) + -0.298 (Dec. 2023 ) + -0.351 (Mar. 2024 ) = C$-1.85 Mil.
Ocumetics Technology's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was -0.112 (Jun. 2023 ) + -0.02 (Sep. 2023 ) + 0 (Dec. 2023 ) + -0.019 (Mar. 2024 ) = C$-0.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ocumetics Technology  (TSXV:OTC) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Mar. 2024, Ocumetics Technology has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Ocumetics Technology Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Ocumetics Technology's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocumetics Technology (TSXV:OTC) Business Description

Traded in Other Exchanges
Address
639 - 5th Avenue S.W., Suite 1250, Calgary, AB, CAN, T2P 0M9
Ocumetics Technology Corp is a Canadian-based research and product development company. The company is engaged in developing an accommodating intraocular lens to eliminate the need for corrective lenses, especially for people over 45 years of age.
Executives
Roger Jewett Director, Senior Officer

Ocumetics Technology (TSXV:OTC) Headlines

No Headlines